Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer – Reuters

1. Novartis’ Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer  Reuters
2. ESMO: Novartis’ Pluvicto slows hormone-sensitive prostate cancer progression  Fierce Pharma
3. Novartis says PSMADDITION data show Novartis Pluvicto(TM) delays progression to end-stage prostate cancer  MarketScreener
4. PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer  MarketScreener

Continue Reading